Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | DRD1 | P21728 | 4/20 | 0.62 |
| ▸ | DRD5 | P21918 | 4/20 | 0.62 |
| ▸ | DRD3 | P35462 | 4/20 | 0.62 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.60 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25192385 | 1.00 | CYP2D6 (0.64) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL25192202 | 0.91 | CYP2D6 (0.53) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL25183522 | 0.91 | HTR7 (0.56) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL18034945 | 0.90 | CYP2D6 (0.62) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| Fumaric Acid SCHEMBL30424752 | 0.89 | HTR7 (0.53) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| Fumaric Acid SCHEMBL25201865 | 0.89 | HTR7 (0.53) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL25774052 | 0.85 | HTR7 (0.54) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL25187618 | 0.85 | DRD2 (0.47) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL25190777 | 0.84 | HTR7 (0.56) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 | |
| SCHEMBL25512795 | 0.84 | HTR7 (0.53) | CYP2D6HSD17B10CYP1A2USP2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360150-A1 | METHODS OF USING NEUROPLASTIC AGENTS AND TERRAFORMING MARS | BRANNOCK METCALF MOLLY CAROLINE (US) | 2025-11-27 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | TERRAN BIOSCIENCES INC. (US) | 2024-02-20 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC. | 2023-09-07 | — | — | US | claimed |
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES INC (US) | 2023-08-17 | — | — | US | claimed |
| WO-2023092045-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122028945-A | Apparatus, systems, and methods for aerosolized drug administration | GH研究爱尔兰有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3861977-B1 | (METH)ACRYLATE, MONOMER COMPOSITION, MOLDED BODY, COMPOSITION FOR DENTAL MATERIAL, AND DENTAL MATERIAL | MITSUI CHEMICALS INC (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4728531-A1 | BIOADAPTIVE THERAPEUTIC ENVIRONMENTS | Therapod LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577232-B2 | N-heterocycle substituted tryptamine derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2026-03-17 | — | — | US | disclosed |
| WO-2022232933-A1 | PERSONALIZED MICRODOSING KITS AND PROTOCOLS BASED ON BIOMETRIC AND MOVEMENT DATA CORRELATED WITH NATURAL PRODUCT QUALITIES | RED LIGHT HOLLAND CORP. (CA) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-11414423-B1 | Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-16 | — | — | US | disclosed |
| CN-110824065-B | Method for detecting embedded lycopene | 南京中科药业有限公司 | 2022-07-26 | — | — | CN | disclosed |
| WO-2022081631-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414423-B1 | Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders | HTR2C, HTR4, HTR2B | CYP2D6 335/4885HSD17B10 866/4885CYP1A2 446/4885 |
| US-20230257385-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | CYP2D6 114/4885HSD17B10 325/4885CYP1A2 344/4885 |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TPH2, TPH1, HTR1D | CYP2D6 428/4885HSD17B10 944/4885CYP1A2 115/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | CYP2D6 1202/4885HSD17B10 3662/4885CYP1A2 1113/4885 |
| US-20230279017-A1 | SALT AND SOLID FORMS OF TABERNANTHALOG | SLC6A2, SLC6A4, SLC6A3 | CYP2D6 114/4885HSD17B10 325/4885CYP1A2 344/4885 |
| US-11905295-B2 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders | FAH, SLC6A3, SLC6A2 | CYP2D6 130/4885HSD17B10 271/4885CYP1A2 401/4885 |
| US-12577232-B2 | N-heterocycle substituted tryptamine derivatives and methods of using | HTR2C, TPH2, HTR4 | CYP2D6 98/4885HSD17B10 2613/4885CYP1A2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.